Cargando…
Creatine, guanidinoacetate and homoarginine in statin-induced myopathy
Our study evaluated the effect of creatine and homoarginine in AGAT- and GAMT-deficient mice after simvastatin exposure. Balestrino and Adriano suggest that guanidinoacetate might explain the difference between AGAT- and GAMT-deficient mice in simvastatin-induced myopathy. We agree with Balestrino a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406479/ https://www.ncbi.nlm.nih.gov/pubmed/32594255 http://dx.doi.org/10.1007/s00726-020-02865-w |
_version_ | 1783567431838466048 |
---|---|
author | Neu, Axel Hornig, Sönke Sasani, Ali Isbrandt, Dirk Gerloff, Christian Tsikas, Dimitris Schwedhelm, Edzard Choe, Chi-un |
author_facet | Neu, Axel Hornig, Sönke Sasani, Ali Isbrandt, Dirk Gerloff, Christian Tsikas, Dimitris Schwedhelm, Edzard Choe, Chi-un |
author_sort | Neu, Axel |
collection | PubMed |
description | Our study evaluated the effect of creatine and homoarginine in AGAT- and GAMT-deficient mice after simvastatin exposure. Balestrino and Adriano suggest that guanidinoacetate might explain the difference between AGAT- and GAMT-deficient mice in simvastatin-induced myopathy. We agree with Balestrino and Adriano that our data shows that (1) creatine possesses a protective potential to ameliorate statin-induced myopathy in humans and mice and (2) homoarginine did not reveal a beneficial effect in statin-induced myopathy. Third, we agree that guanidinoacetate can be phosphorylated and partially compensate for phosphocreatine. In our study, simvastatin-induced damage showed a trend to be less pronounced in GAMT-deficient mice compared with wildtype mice. Therefore, (phospo) guanidinoacetate cannot completely explain the milder phenotype of GAMT-deficient mice, but we agree that it might contribute to ameliorate statin-induced myopathy in GAMT-deficient mice compared with AGAT-deficient mice. Finally, we agree with Balestino and Adriano that AGAT metabolites should further be evaluated as potential treatments in statin-induced myopathy. |
format | Online Article Text |
id | pubmed-7406479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-74064792020-08-13 Creatine, guanidinoacetate and homoarginine in statin-induced myopathy Neu, Axel Hornig, Sönke Sasani, Ali Isbrandt, Dirk Gerloff, Christian Tsikas, Dimitris Schwedhelm, Edzard Choe, Chi-un Amino Acids Letter to the Editor Our study evaluated the effect of creatine and homoarginine in AGAT- and GAMT-deficient mice after simvastatin exposure. Balestrino and Adriano suggest that guanidinoacetate might explain the difference between AGAT- and GAMT-deficient mice in simvastatin-induced myopathy. We agree with Balestrino and Adriano that our data shows that (1) creatine possesses a protective potential to ameliorate statin-induced myopathy in humans and mice and (2) homoarginine did not reveal a beneficial effect in statin-induced myopathy. Third, we agree that guanidinoacetate can be phosphorylated and partially compensate for phosphocreatine. In our study, simvastatin-induced damage showed a trend to be less pronounced in GAMT-deficient mice compared with wildtype mice. Therefore, (phospo) guanidinoacetate cannot completely explain the milder phenotype of GAMT-deficient mice, but we agree that it might contribute to ameliorate statin-induced myopathy in GAMT-deficient mice compared with AGAT-deficient mice. Finally, we agree with Balestino and Adriano that AGAT metabolites should further be evaluated as potential treatments in statin-induced myopathy. Springer Vienna 2020-06-27 2020 /pmc/articles/PMC7406479/ /pubmed/32594255 http://dx.doi.org/10.1007/s00726-020-02865-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Letter to the Editor Neu, Axel Hornig, Sönke Sasani, Ali Isbrandt, Dirk Gerloff, Christian Tsikas, Dimitris Schwedhelm, Edzard Choe, Chi-un Creatine, guanidinoacetate and homoarginine in statin-induced myopathy |
title | Creatine, guanidinoacetate and homoarginine in statin-induced myopathy |
title_full | Creatine, guanidinoacetate and homoarginine in statin-induced myopathy |
title_fullStr | Creatine, guanidinoacetate and homoarginine in statin-induced myopathy |
title_full_unstemmed | Creatine, guanidinoacetate and homoarginine in statin-induced myopathy |
title_short | Creatine, guanidinoacetate and homoarginine in statin-induced myopathy |
title_sort | creatine, guanidinoacetate and homoarginine in statin-induced myopathy |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406479/ https://www.ncbi.nlm.nih.gov/pubmed/32594255 http://dx.doi.org/10.1007/s00726-020-02865-w |
work_keys_str_mv | AT neuaxel creatineguanidinoacetateandhomoarginineinstatininducedmyopathy AT hornigsonke creatineguanidinoacetateandhomoarginineinstatininducedmyopathy AT sasaniali creatineguanidinoacetateandhomoarginineinstatininducedmyopathy AT isbrandtdirk creatineguanidinoacetateandhomoarginineinstatininducedmyopathy AT gerloffchristian creatineguanidinoacetateandhomoarginineinstatininducedmyopathy AT tsikasdimitris creatineguanidinoacetateandhomoarginineinstatininducedmyopathy AT schwedhelmedzard creatineguanidinoacetateandhomoarginineinstatininducedmyopathy AT choechiun creatineguanidinoacetateandhomoarginineinstatininducedmyopathy |